Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study
Background The outcomes of coronavirus disease 2019 (COVID-19) treatment have improved due to vaccination and the establishment of better treatment regimens. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, and the corresp...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-10, Vol.17 (10), p.e0273134-e0273134 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0273134 |
|---|---|
| container_issue | 10 |
| container_start_page | e0273134 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Ogawa, Fumihiro Oi, Yasufumi Honzawa, Hiroshi Misawa, Naho Takeda, Tomoaki Kikuchi, Yushi Fukui, Ryosuke Tanaka, Katsushi Kano, Daiki Kato, Hideaki Abe, Takeru Takeuchi, Ichiro |
| description | Background The outcomes of coronavirus disease 2019 (COVID-19) treatment have improved due to vaccination and the establishment of better treatment regimens. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, and the corresponding changes in the characteristics of the disease present new challenges in patient management. This study aimed to analyze predictors of COVID-19 severity caused by the delta and omicron variants of SARS-CoV-2. Methods We retrospectively analyzed the data of patients who were admitted for COVID-19 at Yokohama City University Hospital from August 2021 to March 2022. Results A total of 141 patients were included in this study. Of these, 91 had moderate COVID-19, whereas 50 had severe COVID-19. There were significant differences in sex, vaccination status, dyspnea, sore throat symptoms, and body mass index (BMI) (p |
| doi_str_mv | 10.1371/journal.pone.0273134 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2728447902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A724025487</galeid><doaj_id>oai_doaj_org_article_e1eea3f405fe4fd09af0b968fd1a0c19</doaj_id><sourcerecordid>A724025487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c735t-58870bfcb2eb267e95c1866ca9f24c15df64406f462072b48de484241cb090503</originalsourceid><addsrcrecordid>eNqNk1uLEzEUxwdRcK1-A8GAIApOTTKZG4JQ6q2wUNhqX0MmOWmzTJOaZIr99qZ2lK3sg-Qh4eSX_7nknCx7TvCUFDV5d-sGb0U_3TsLU0zrghTsQXZF2oLmFcXFwzvnx9mTEG4xLoumqq4ytYIDeBOPaO9BGRmdD8hpNF-uFx9z0iJj0Wp2s8rnbp1TdBDeCBvfIgV9FEhYhdzOSO8s2icZp96jYOymByTBRvAoxEEdn2aPtOgDPBv3Sfb986dv86_59fLLYj67zmVdlDEvm6bGnZYdhY5WNbSlJClIKVpNmSSl0hVjuNIs5VHTjjUKWMMoI7LDLS5xMclenHX3vQt8rErgtKYNY3WLaSIWZ0I5ccv33uyEP3InDP9tcH7DhY9G9sCBAIhCM1xqYFrhVmjctVWjFRFYpnpOsg-jt6HbgTol7EV_IXp5Y82Wb9yBt2VblrRIAq9HAe9-DBAi35kgoe-FBTeMcVesJlVCX_6D3p_dSG1ESsBY7ZJfeRLls5oyTEvW1Ima3kOlpSB9ZWohbZL94sGbiweJifAzbsQQAl-sbv6fXa4v2Vd32C2IPm6D64donA2XIDuDqdFC8KD_FplgfpqAP9Xgpwng4wQUvwCzIPaT</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728447902</pqid></control><display><type>article</type><title>Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ogawa, Fumihiro ; Oi, Yasufumi ; Honzawa, Hiroshi ; Misawa, Naho ; Takeda, Tomoaki ; Kikuchi, Yushi ; Fukui, Ryosuke ; Tanaka, Katsushi ; Kano, Daiki ; Kato, Hideaki ; Abe, Takeru ; Takeuchi, Ichiro</creator><contributor>Liu, Benjamin M.</contributor><creatorcontrib>Ogawa, Fumihiro ; Oi, Yasufumi ; Honzawa, Hiroshi ; Misawa, Naho ; Takeda, Tomoaki ; Kikuchi, Yushi ; Fukui, Ryosuke ; Tanaka, Katsushi ; Kano, Daiki ; Kato, Hideaki ; Abe, Takeru ; Takeuchi, Ichiro ; Liu, Benjamin M.</creatorcontrib><description><![CDATA[Background The outcomes of coronavirus disease 2019 (COVID-19) treatment have improved due to vaccination and the establishment of better treatment regimens. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, and the corresponding changes in the characteristics of the disease present new challenges in patient management. This study aimed to analyze predictors of COVID-19 severity caused by the delta and omicron variants of SARS-CoV-2. Methods We retrospectively analyzed the data of patients who were admitted for COVID-19 at Yokohama City University Hospital from August 2021 to March 2022. Results A total of 141 patients were included in this study. Of these, 91 had moderate COVID-19, whereas 50 had severe COVID-19. There were significant differences in sex, vaccination status, dyspnea, sore throat symptoms, and body mass index (BMI) (p <0.0001, p <0.001, p <0.001, p = 0.02, p< 0.0001, respectively) between the moderate and severe COVID-19 groups. Regarding comorbidities, smoking habit and renal dysfunction were significantly different between the two groups (p = 0.007 and p = 0.01, respectively). Regarding laboratory data, only LDH level on the first day of hospitalization was significantly different between the two groups (p<0.001). Multiple logistic regression analysis revealed that time from the onset of COVID-19 to hospitalization, BMI, smoking habit, and LDH level were significantly different between the two groups (p<0.03, p = 0.039, p = 0.008, p<0.001, respectively). The cut-off value for the time from onset of COVID-19 to hospitalization was four days (sensitivity, 0.73; specificity, 0.70). Conclusions Time from the onset of COVID-19 to hospitalization is the most important factor in the prevention of the aggravation of COVID-19 caused by the delta and omicron SARS-CoV-2 variants. Appropriate medical management within four days after the onset of COVID-19 is essential for preventing the progression of COVID-19, especially in patients with smoking habits.]]></description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0273134</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Age ; Antiviral drugs ; Biology and life sciences ; Biomarkers ; Blood ; Body mass ; Body mass index ; Body size ; Classification ; Comorbidity ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Dyspnea ; Health aspects ; Health services ; Hemodialysis ; Hospitalization ; Hospitals ; Immunization ; Intensive care ; Laboratories ; Medical case management ; Medicine and Health Sciences ; Pandemics ; Patients ; Pharyngitis ; Physical Sciences ; Pneumonia ; Regression analysis ; Renal function ; Respiration ; Respiratory diseases ; Services ; Severe acute respiratory syndrome coronavirus 2 ; Signs and symptoms ; Smokers ; Smoking ; Social Sciences ; Vaccination ; Ventilators ; Viral diseases</subject><ispartof>PloS one, 2022-10, Vol.17 (10), p.e0273134-e0273134</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Ogawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Ogawa et al 2022 Ogawa et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c735t-58870bfcb2eb267e95c1866ca9f24c15df64406f462072b48de484241cb090503</citedby><cites>FETCH-LOGICAL-c735t-58870bfcb2eb267e95c1866ca9f24c15df64406f462072b48de484241cb090503</cites><orcidid>0000-0002-7069-9334 ; 0000-0002-7853-5721</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595523/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595523/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids></links><search><contributor>Liu, Benjamin M.</contributor><creatorcontrib>Ogawa, Fumihiro</creatorcontrib><creatorcontrib>Oi, Yasufumi</creatorcontrib><creatorcontrib>Honzawa, Hiroshi</creatorcontrib><creatorcontrib>Misawa, Naho</creatorcontrib><creatorcontrib>Takeda, Tomoaki</creatorcontrib><creatorcontrib>Kikuchi, Yushi</creatorcontrib><creatorcontrib>Fukui, Ryosuke</creatorcontrib><creatorcontrib>Tanaka, Katsushi</creatorcontrib><creatorcontrib>Kano, Daiki</creatorcontrib><creatorcontrib>Kato, Hideaki</creatorcontrib><creatorcontrib>Abe, Takeru</creatorcontrib><creatorcontrib>Takeuchi, Ichiro</creatorcontrib><title>Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study</title><title>PloS one</title><description><![CDATA[Background The outcomes of coronavirus disease 2019 (COVID-19) treatment have improved due to vaccination and the establishment of better treatment regimens. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, and the corresponding changes in the characteristics of the disease present new challenges in patient management. This study aimed to analyze predictors of COVID-19 severity caused by the delta and omicron variants of SARS-CoV-2. Methods We retrospectively analyzed the data of patients who were admitted for COVID-19 at Yokohama City University Hospital from August 2021 to March 2022. Results A total of 141 patients were included in this study. Of these, 91 had moderate COVID-19, whereas 50 had severe COVID-19. There were significant differences in sex, vaccination status, dyspnea, sore throat symptoms, and body mass index (BMI) (p <0.0001, p <0.001, p <0.001, p = 0.02, p< 0.0001, respectively) between the moderate and severe COVID-19 groups. Regarding comorbidities, smoking habit and renal dysfunction were significantly different between the two groups (p = 0.007 and p = 0.01, respectively). Regarding laboratory data, only LDH level on the first day of hospitalization was significantly different between the two groups (p<0.001). Multiple logistic regression analysis revealed that time from the onset of COVID-19 to hospitalization, BMI, smoking habit, and LDH level were significantly different between the two groups (p<0.03, p = 0.039, p = 0.008, p<0.001, respectively). The cut-off value for the time from onset of COVID-19 to hospitalization was four days (sensitivity, 0.73; specificity, 0.70). Conclusions Time from the onset of COVID-19 to hospitalization is the most important factor in the prevention of the aggravation of COVID-19 caused by the delta and omicron SARS-CoV-2 variants. Appropriate medical management within four days after the onset of COVID-19 is essential for preventing the progression of COVID-19, especially in patients with smoking habits.]]></description><subject>Age</subject><subject>Antiviral drugs</subject><subject>Biology and life sciences</subject><subject>Biomarkers</subject><subject>Blood</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Classification</subject><subject>Comorbidity</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Dyspnea</subject><subject>Health aspects</subject><subject>Health services</subject><subject>Hemodialysis</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Immunization</subject><subject>Intensive care</subject><subject>Laboratories</subject><subject>Medical case management</subject><subject>Medicine and Health Sciences</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Pharyngitis</subject><subject>Physical Sciences</subject><subject>Pneumonia</subject><subject>Regression analysis</subject><subject>Renal function</subject><subject>Respiration</subject><subject>Respiratory diseases</subject><subject>Services</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Signs and symptoms</subject><subject>Smokers</subject><subject>Smoking</subject><subject>Social Sciences</subject><subject>Vaccination</subject><subject>Ventilators</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1uLEzEUxwdRcK1-A8GAIApOTTKZG4JQ6q2wUNhqX0MmOWmzTJOaZIr99qZ2lK3sg-Qh4eSX_7nknCx7TvCUFDV5d-sGb0U_3TsLU0zrghTsQXZF2oLmFcXFwzvnx9mTEG4xLoumqq4ytYIDeBOPaO9BGRmdD8hpNF-uFx9z0iJj0Wp2s8rnbp1TdBDeCBvfIgV9FEhYhdzOSO8s2icZp96jYOymByTBRvAoxEEdn2aPtOgDPBv3Sfb986dv86_59fLLYj67zmVdlDEvm6bGnZYdhY5WNbSlJClIKVpNmSSl0hVjuNIs5VHTjjUKWMMoI7LDLS5xMclenHX3vQt8rErgtKYNY3WLaSIWZ0I5ccv33uyEP3InDP9tcH7DhY9G9sCBAIhCM1xqYFrhVmjctVWjFRFYpnpOsg-jt6HbgTol7EV_IXp5Y82Wb9yBt2VblrRIAq9HAe9-DBAi35kgoe-FBTeMcVesJlVCX_6D3p_dSG1ESsBY7ZJfeRLls5oyTEvW1Ima3kOlpSB9ZWohbZL94sGbiweJifAzbsQQAl-sbv6fXa4v2Vd32C2IPm6D64donA2XIDuDqdFC8KD_FplgfpqAP9Xgpwng4wQUvwCzIPaT</recordid><startdate>20221025</startdate><enddate>20221025</enddate><creator>Ogawa, Fumihiro</creator><creator>Oi, Yasufumi</creator><creator>Honzawa, Hiroshi</creator><creator>Misawa, Naho</creator><creator>Takeda, Tomoaki</creator><creator>Kikuchi, Yushi</creator><creator>Fukui, Ryosuke</creator><creator>Tanaka, Katsushi</creator><creator>Kano, Daiki</creator><creator>Kato, Hideaki</creator><creator>Abe, Takeru</creator><creator>Takeuchi, Ichiro</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7069-9334</orcidid><orcidid>https://orcid.org/0000-0002-7853-5721</orcidid></search><sort><creationdate>20221025</creationdate><title>Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study</title><author>Ogawa, Fumihiro ; Oi, Yasufumi ; Honzawa, Hiroshi ; Misawa, Naho ; Takeda, Tomoaki ; Kikuchi, Yushi ; Fukui, Ryosuke ; Tanaka, Katsushi ; Kano, Daiki ; Kato, Hideaki ; Abe, Takeru ; Takeuchi, Ichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c735t-58870bfcb2eb267e95c1866ca9f24c15df64406f462072b48de484241cb090503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Antiviral drugs</topic><topic>Biology and life sciences</topic><topic>Biomarkers</topic><topic>Blood</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Classification</topic><topic>Comorbidity</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Dyspnea</topic><topic>Health aspects</topic><topic>Health services</topic><topic>Hemodialysis</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Immunization</topic><topic>Intensive care</topic><topic>Laboratories</topic><topic>Medical case management</topic><topic>Medicine and Health Sciences</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Pharyngitis</topic><topic>Physical Sciences</topic><topic>Pneumonia</topic><topic>Regression analysis</topic><topic>Renal function</topic><topic>Respiration</topic><topic>Respiratory diseases</topic><topic>Services</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Signs and symptoms</topic><topic>Smokers</topic><topic>Smoking</topic><topic>Social Sciences</topic><topic>Vaccination</topic><topic>Ventilators</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogawa, Fumihiro</creatorcontrib><creatorcontrib>Oi, Yasufumi</creatorcontrib><creatorcontrib>Honzawa, Hiroshi</creatorcontrib><creatorcontrib>Misawa, Naho</creatorcontrib><creatorcontrib>Takeda, Tomoaki</creatorcontrib><creatorcontrib>Kikuchi, Yushi</creatorcontrib><creatorcontrib>Fukui, Ryosuke</creatorcontrib><creatorcontrib>Tanaka, Katsushi</creatorcontrib><creatorcontrib>Kano, Daiki</creatorcontrib><creatorcontrib>Kato, Hideaki</creatorcontrib><creatorcontrib>Abe, Takeru</creatorcontrib><creatorcontrib>Takeuchi, Ichiro</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogawa, Fumihiro</au><au>Oi, Yasufumi</au><au>Honzawa, Hiroshi</au><au>Misawa, Naho</au><au>Takeda, Tomoaki</au><au>Kikuchi, Yushi</au><au>Fukui, Ryosuke</au><au>Tanaka, Katsushi</au><au>Kano, Daiki</au><au>Kato, Hideaki</au><au>Abe, Takeru</au><au>Takeuchi, Ichiro</au><au>Liu, Benjamin M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study</atitle><jtitle>PloS one</jtitle><date>2022-10-25</date><risdate>2022</risdate><volume>17</volume><issue>10</issue><spage>e0273134</spage><epage>e0273134</epage><pages>e0273134-e0273134</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract><![CDATA[Background The outcomes of coronavirus disease 2019 (COVID-19) treatment have improved due to vaccination and the establishment of better treatment regimens. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, and the corresponding changes in the characteristics of the disease present new challenges in patient management. This study aimed to analyze predictors of COVID-19 severity caused by the delta and omicron variants of SARS-CoV-2. Methods We retrospectively analyzed the data of patients who were admitted for COVID-19 at Yokohama City University Hospital from August 2021 to March 2022. Results A total of 141 patients were included in this study. Of these, 91 had moderate COVID-19, whereas 50 had severe COVID-19. There were significant differences in sex, vaccination status, dyspnea, sore throat symptoms, and body mass index (BMI) (p <0.0001, p <0.001, p <0.001, p = 0.02, p< 0.0001, respectively) between the moderate and severe COVID-19 groups. Regarding comorbidities, smoking habit and renal dysfunction were significantly different between the two groups (p = 0.007 and p = 0.01, respectively). Regarding laboratory data, only LDH level on the first day of hospitalization was significantly different between the two groups (p<0.001). Multiple logistic regression analysis revealed that time from the onset of COVID-19 to hospitalization, BMI, smoking habit, and LDH level were significantly different between the two groups (p<0.03, p = 0.039, p = 0.008, p<0.001, respectively). The cut-off value for the time from onset of COVID-19 to hospitalization was four days (sensitivity, 0.73; specificity, 0.70). Conclusions Time from the onset of COVID-19 to hospitalization is the most important factor in the prevention of the aggravation of COVID-19 caused by the delta and omicron SARS-CoV-2 variants. Appropriate medical management within four days after the onset of COVID-19 is essential for preventing the progression of COVID-19, especially in patients with smoking habits.]]></abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0273134</doi><tpages>e0273134</tpages><orcidid>https://orcid.org/0000-0002-7069-9334</orcidid><orcidid>https://orcid.org/0000-0002-7853-5721</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-10, Vol.17 (10), p.e0273134-e0273134 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2728447902 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Age Antiviral drugs Biology and life sciences Biomarkers Blood Body mass Body mass index Body size Classification Comorbidity Coronaviruses COVID-19 COVID-19 vaccines Dyspnea Health aspects Health services Hemodialysis Hospitalization Hospitals Immunization Intensive care Laboratories Medical case management Medicine and Health Sciences Pandemics Patients Pharyngitis Physical Sciences Pneumonia Regression analysis Renal function Respiration Respiratory diseases Services Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Smokers Smoking Social Sciences Vaccination Ventilators Viral diseases |
| title | Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T06%3A48%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severity%20predictors%20of%20COVID-19%20in%20SARS-CoV-2%20variant,%20delta%20and%20omicron%20period;%20single%20center%20study&rft.jtitle=PloS%20one&rft.au=Ogawa,%20Fumihiro&rft.date=2022-10-25&rft.volume=17&rft.issue=10&rft.spage=e0273134&rft.epage=e0273134&rft.pages=e0273134-e0273134&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0273134&rft_dat=%3Cgale_plos_%3EA724025487%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2728447902&rft_id=info:pmid/&rft_galeid=A724025487&rft_doaj_id=oai_doaj_org_article_e1eea3f405fe4fd09af0b968fd1a0c19&rfr_iscdi=true |